Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to $735.1 million.

  • Madrigal Pharmaceuticals' Cash from Financing Activities rose 3071.36% to $236.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.8 million, marking a year-over-year decrease of 77.68%. This contributed to the annual value of $735.1 million for FY2024, which is 23.52% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $735.1 million for FY2024, which was up 23.52% from $595.1 million recorded in FY2023.
  • Madrigal Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $735.1 million during FY2024, with a 5-year trough of $5.1 million in FY2020.
  • For the 3-year period, Madrigal Pharmaceuticals' Cash from Financing Activities averaged around $547.9 million, with its median value being $595.1 million (2023).
  • Data for Madrigal Pharmaceuticals' Cash from Financing Activities shows a peak YoY spiked of 3,265.51% (in 2021) over the last 5 years.
  • Madrigal Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $5.1 million in 2020, then spiked by 3,265.51% to $171.2 million in 2021, then spiked by 83.05% to $313.5 million in 2022, then surged by 89.86% to $595.1 million in 2023, then rose by 23.52% to $735.1 million in 2024.